CRISPR Therapeutics (NASDAQ:CRSP) Posts Earnings Results, Beats Estimates By $0.41 EPS

CRISPR Therapeutics (NASDAQ:CRSP) released its earnings results on Tuesday. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41, Briefing.com reports. The firm had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. During the same period last year, the business earned ($1.41) earnings per share.

CRISPR Therapeutics Stock Down 0.4 %

Shares of CRSP traded down $0.23 during trading hours on Friday, reaching $51.65. The stock had a trading volume of 616,115 shares, compared to its average volume of 1,452,587. CRISPR Therapeutics has a 52 week low of $43.42 and a 52 week high of $91.10. The firm has a 50-day moving average of $47.38 and a 200 day moving average of $52.24. The company has a market cap of $4.39 billion, a P/E ratio of -16.06 and a beta of 1.67.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CRSP shares. Chardan Capital decreased their target price on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday. Rodman & Renshaw assumed coverage on CRISPR Therapeutics in a report on Friday, August 2nd. They issued a “buy” rating and a $90.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Thursday. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $74.94.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the transaction, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.